- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: MagdaRau GERMANY
Co Author(s): Tsontcho Ianchulev J. Garcia-Feijoo Salvatore Grisanti Pravoslava Guguchkova
Back to previous
Evaluate the safety and outcomes of suprachoroidal micro-stent implantation as a treatment for open-angle glaucoma,
: Multi-site clinical study in Europe and Canada.
In prospective, multicenter interventional case series (DUETTE study),the CyPass Micro-Stent (Transcend Medical, Inc, Menlo Park, CA)was implanted in 65 subjects for whom medical therapy was insufficient to control intraocular pressure into the supraciliary space through a 1.5 mm incision. Safety data, including adverse events, complications, intraocular pressure, and medications, are reported up to 12 months postoperative.
68% of subjects were on 2 or more medications and all had a baseline medicated IOP ≥ 21 mmHg. Mean medicated IOP at baseline was 24.3 mmHg. There were no cases of suprachoroidal hemorrhage, bleb-related complications, retinal complications or hypotony maculopathy. At 12 months after surgery, mean IOP was 15.2 mmHg with a 41% reduction in IOP from baseline. 86% of patients had a >20% reduction in IOP with a concomitant reduction or no change in IOP-lowering medications.
The supraciliary CyPass Micro-Stent provided safe and sustained IOP reduction in patients with primary open-angle glaucoma. FINANCIAL INTEREST: NONE